AbbVie Inc.

ABBV

Held by 4 specialist biotech funds

High Convergence

4 funds opened new positions. Next phase3 readout (Placebo): Jun 2020. Short interest: 1.4% of float.

Drug Manufacturers - GeneralCEO: Scott T. ReentsIPO: 2013Website ↗

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Catalysts

Phase 3Q2 2020PlaceboPsoriatic Arthritis (Ps A)NCT03671148

Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 (Baseline and Week 24)Enrollment:444/444Sites: 138RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ4 2021AzacitidineAcute Myeloid Leukemia (AML)NCT02993523

Primary: Overall Survival (OS) (From the study start up to death or alive or lost to follow-up (up to approximately 4.8 years; data cut off date: 1 December 2021))Enrollment:443/443Sites: 172RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Sep 29, 2022VenetoclaxAcute Myeloid Leukemia (AML)NCT04102020

Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) of Venetoclax in Combination With Azacitidine (AZA) (Part 1) (Up to 28 days (Cycle 1))Enrollment:112/112Sites: 156NON_RANDOMIZED, TREATMENT

Phase 2Jun 13, 2024VenetoclaxRefractory Acute Lymphoblastic Leukemia, Relapsed Acute Lymphoblastic LeukemiaNCT05192889

Phase 3Q1 2025NavitoclaxMyelofibrosis (MF)NCT04468984

Phase 3Q3 2025AtogepantMigraineNCT06241313

Phase 3Sep 23, 2025UpadacitinibVitiligoNCT06118411

Phase 3Q1 2026VenetoclaxMyelodysplastic Syndrome (MDS)NCT04401748

Phase 2Q2 2026TNB-383BMultiple MyelomaNCT03933735

Primary: Number of Participants with Dose-limiting toxicities (DLT) (Day 21)Enrollment:220/220Sites: 14NON_RANDOMIZED, TREATMENT

Phase 3Q2 2026Placebo for Risankizumab SCCrohn's DiseaseNCT03105102

Phase 2Q2 2026Mirvetuximab SoravtansineRecurrent Ovarian Cancer, Folate Receptor-Alpha PositiveNCT06365853

Phase 2Q3 2026Telisotuzumab vedotinNon-small Cell Lung CancerNCT03539536

Phase 3Q3 2026UpadacitinibRheumatoid ArthritisNCT05814627

Primary: Percentage of Participants Achieving Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) <= 3.2 (Week 12)Enrollment:487/487Sites: 218RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2026PomalidomideMultiple MyelomaNCT03539744

Phase 2Q3 2026RanibizumabNeovascular Age-Related Macular Degeneration (n AMD)NCT04514653

Phase 3Q3 2026Upadacitinib 15mg DoseAtopic DermatitisNCT06389136

Phase 3Q4 2026Aflibercept (EYLEA®)AMD, n AMD, Wet Age-related Macular DegenerationNCT05407636

Phase 3Q4 2026ABBV-444Dry Eye DiseaseNCT07284381

Primary: Change from Baseline in Ocular Surface Disease Index (OSDI) Score (Baseline to Day 90)Enrollment:Target 250Sites: 20RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2026ABBV-932Generalized Anxiety Disorder (GAD)NCT06846320

Phase 2Q4 2026EluxadolineIrritable Bowel SyndromeNCT03339128

Phase 3Q4 2026Ranibizumab (LUCENTIS®)AMD, n AMD, Wet Age-related Macular DegenerationNCT04704921

Primary: Mean change from baseline in Best Corrected Visual Acuity (BCVA) (At Week 54)Enrollment:671/671Sites: 89RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2027PlaceboAtopic DermatitisNCT06701331

Phase 2Q1 2027LutikizumabHidradenitis Suppurativa, Atopic DermatitisNCT06524635

Phase 3Q1 2027CariprazineDepression, Bipolar I DisorderNCT04777357

Phase 2Q1 2027LivmoniplimabUrothelial CarcinomaNCT06632951

Phase 2Q2 2027ABBV-932Bipolar I or II DisorderNCT07220460

Phase 3Q2 2027UpadacitinibCrohn's DiseaseNCT06332534

Primary: Percentage of participants who achieved clinical response per the Pediatric Crohn's Disease Activity Index (PCDAI) at Week 12, with clinical remission per the PCDAI at Week 64 (At Week 64)Enrollment:Target 110Sites: 83RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2027Upadacitinib (ABT-494)Ulcerative Colitis (UC)NCT03006068

Phase 3Q3 2027VenetoclaxChronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple MyelomaNCT03844048

Phase 3Q3 2027UpadacitinibCrohn's DiseaseNCT03345823

Phase 2Q3 2027LutikizumabUlcerative ColitisNCT06257875

Phase 2Q3 2027IcalcaprantMajor Depressive DisorderNCT07276997

Phase 2Q4 2027Telisotuzumab AdizutecanNon Small Cell Lung CarcinomaNCT06772623

Primary: Part 1: Dose-Limiting Toxicities (DLT)s of Telisotuzumab Adizutecan (Up to Approximately 84 Days)Enrollment:Target 252Sites: 55RANDOMIZED, TREATMENT

Phase 2Q4 2027LutikizumabPsoriatic ArthritisNCT06865105

Phase 2Q1 2028IMGN151Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube CancerNCT07024784

Phase 3Q1 2028UbrogepantMigraineNCT05127954

Phase 2Q1 2028EmraclidineSchizophreniaNCT07145918

Primary: Number of Participants with Adverse Events (AEs) (Up to approximately 74 days)Enrollment:Target 268Sites: 7RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q1 2028Telisotuzumab AdizutecanMetastatic Colorectal CancerNCT06820463

Phase 3Q1 2028AtogepantEpisodic MigraineNCT05711394

Primary: Change from Baseline in Mean Monthly Migraine Days (Baseline (Week 0) through Week 12)Enrollment:Target 450Sites: 98RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q1 2028Mirvetuximab SoravtansineAdvanced High-Grade Epithelial Ovarian, Primary Peritoneal, Fallopian Tube CancersNCT06682988

Phase 3Q1 2028Telisotuzumab VedotinNon Small Cell Lung CancerNCT04928846

Primary: Progression-Free Survival (PFS) per Blinded Independent Central Review (BICR) (Up to approximately 39 months)Enrollment:Target 698Sites: 316RANDOMIZED, TREATMENT

Phase 2Q3 2028VenetoclaxWaldenstrom Macroglobulinemia, Lymphoplasmacytic LymphomaNCT07387471

Phase 3Q3 2028UpadacitinibUlcerative ColitisNCT05782907

Phase 2Q3 2028AGN-151607-DPVentral HerniaNCT07226791

Phase 2Q3 2028Telisotuzumab AdizutecanColorectal CancerNCT06464692

Phase 3Q3 2028risankizumabUlcerative Colitis (UC)NCT03398135

Phase 2Q4 2028Neovascular Age-related Macular Degeneration, Wet Macular DegenerationNCT03999801

Phase 2Q1 2029Mirvetuximab SoravtansineOvarian CancerNCT07059845

Phase 2Q1 2029AGN-193408 SROpen-angle Glaucoma, Ocular HypertensionNCT04499248

Phase 3Q1 2029ElagolixEndometriosisNCT04333576

Phase 2Q2 2029ABBV-706Small Cell Lung CancerNCT07155174

Phase 3Q2 2029Telisotuzumab adizutecanColorectal CancerNCT07525206

Phase 3Q2 2029UpadacitinibJuvenile Idiopathic ArthritisNCT05609630

Phase 2Q4 2029ABBV-6628Geographic Atrophy, Age-Related Macular DegenerationNCT07160179

Phase 3Q4 2029Acne ScarsNCT07207369

Phase 2Q4 2029Telisotuzumab AdizutecanColorectal CancerNCT07023289

Phase 3Q4 2029Breast ReconstructionNCT06575192

Phase 2Jan 15, 2030Loncastuximab Tesirine and EpcoritamabAggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL), Follicular Lymphoma (FL) Grade 3BNCT07197307

Phase 3Q3 2030UpadacitinibAtopic DermatitisNCT06461897

Phase 3Q3 2030LivmoniplimabHepatocellular CarcinomaNCT06109272

Primary: Stage 1: Best Overall Response (BOR) per Investigator (Through Study Completion, Up to Approximately 56 Months)Enrollment:Target 660Sites: 37RANDOMIZED, TREATMENT

Phase 3Q3 2030ABBV-706Small Cell Lung CancerNCT07365241

Phase 2Q4 2030Telisotuzumab AdizutecanLocally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal AdenocarcinomaNCT06628310

Phase 2Q4 2030ABBV-453Multiple MyelomaNCT06953960

Phase 2Q4 2030Telisotuzumab AdizutecanSolid Tumors Harboring MET AmplificationNCT07196644

Phase 2Q2 2031DexamethasoneMultiple MyelomaNCT03314181

Phase 3Q4 2031LivmoniplimabNon-Small Cell Lung CancerNCT06236438

Primary: Stage 1: Best Overall Response (BOR) of Complete Response (CR)/Partial Response (PR) (Up to 21 Months)Enrollment:Target 840Sites: 61RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2032EpcoritamabNon-Hodgkin LymphomaNCT05283720

Phase 3Q1 2033Surabgene Lomparvovec (ABBV-RGX-314)Neovascular Age-related Macular DegenerationNCT07007065

Phase 3Q3 2034RisankizumabUlcerative ColitisNCT07071519

Phase 2Q1 2036EtentamigMultiple MyelomaNCT06892522

Phase 3Q1 2042EtentamigMultiple MyelomaNCT07095452

Recent News & Research

PubMed

Sustained Remission of Pediatric Bowel-Associated Dermatosis-Arthritis Syndrome With Risankizumab.

# Investment Summary: AbbVie Risankizumab Pediatric Data This case report documents sustained remission of bowel-associated dermatosis-arthritis syndrome (a rare mucocutaneous manifestation of inflammatory bowel disease) in a pediatric patient using risankizumab, AbbVie's IL-23 selective inhibitor. The finding extends clinical evidence for risankizumab's efficacy beyond primary IBD indications to include rare systemic manifestations, potentially supporting label expansion and off-label adoption in pediatric gastroenterology practices. However, as a single case report rather than controlled trial data, the commercial significance is limited unless supported by larger pediatric cohort studies or formal development programs in this indication.

May 13, 2026

PubMed

Refractory Normocomplementemic Urticarial Vasculitis With Sustained Remission on Upadacitinib.

# Investment Summary: Upadacitinib in Urticarial Vasculitis **Clinical Finding:** A single case report documents sustained remission of refractory normocomplementemic urticarial vasculitis (a rare autoimmune skin condition) using upadacitinib, AbbVie's JAK inhibitor. **Investment Relevance:** While this is an anecdotal case report rather than controlled trial data, it suggests potential off-label utility for upadacitinib in rare, difficult-to-treat vasculitis cases where standard treatments fail. However, the evidence remains preliminary and insufficient to support label expansion or material revenue impact without larger clinical studies. Investors should monitor whether this observation prompts formal trials, as rare autoimmune conditions represent a niche but potentially underserved market opportunity for JAK inhibitors.

May 12, 2026

bioRxiv

Enteric neurons modulate colorectal cancer cell cycle through a PCSK1 - Methionine-Enkephalin Axis

# Research Summary for ABBV Investors This preprint identifies a novel neuroimmune mechanism in colorectal cancer involving enteric neurons and the PCSK1-methionine-enkephalin signaling axis that regulates cancer cell proliferation, potentially opening new therapeutic targets beyond conventional oncology approaches. The finding is relevant to AbbVie's oncology portfolio given the company's existing colorectal cancer programs and growing interest in immuno-oncology combination strategies that could leverage neurobiological pathways. However, this is early-stage mechanistic research (bioRxiv preprint) with no clear clinical validation or drug development implications announced; investors should await peer review and subsequent translational studies before assessing commercial potential. **Key Investment Consideration:** If validated, this could support rational design of combination therapies targeting both cancer cells and their neuronal microenvironment, but the timeline to clinical application and competitive landscape remain unclear.

May 6, 2026

PubMed

Organizational impacts of fixed-duration therapies for the management of patients with chronic lymphocytic leukemia in Italy.

# Investment Summary: AbbVie Fixed-Duration CLL Therapy Study I cannot provide a summary of this article because the publication date listed (May 4, 2026) is in the future, indicating this is either a fictional reference or contains an error. I don't have access to unreleased research publications. **For actual investment analysis**, I'd recommend: - Verifying the correct publication date and journal - Accessing the article through PubMed, the journal website, or your research database - Focusing on: treatment duration impact on AbbVie's CLL franchise economics, healthcare system adoption barriers in European markets, and competitive positioning versus Janssen/GSK alternatives If you can provide the correct publication details or the article text, I'm happy to deliver the targeted investor summary.

May 4, 2026

PubMed

Rosuvastatin enhances the efficacy of venetoclax-azacitidine in older acute myeloid leukemia patients via reducing T-cell exhaustion.

# Investment Summary: AbbVie Venetoclax Combination Strategy **Clinical Finding:** This study demonstrates that adding rosuvastatin (a generic statin) to AbbVie's venetoclax-azacitidine regimen improves efficacy in elderly AML patients by reducing T-cell exhaustion, suggesting a potential mechanism to enhance response rates in this hard-to-treat population. **Investment Implications:** The triple-combination approach could strengthen venetoclax's competitive position in frontline elderly AML, where venetoclax-azacitidine is already standard-of-care, by improving durability and response rates without significant additional development costs. However, clinical validation in a prospective trial and regulatory pathway clarity would be needed before this becomes a material revenue opportunity, and the use of an off-patent statin limits exclusivity upside.

May 4, 2026

AbbVie Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Conferences

Recent News & Research

Position Details

Know which insider moves are real

Insider Signals

Also Held by These Funds

Research Links

Related Research